The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Development services for gene and cell therapies is planned to begin first in 2025
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Five batches across four programs of Biocon Academy participated in the graduation ceremony
10+ emerging markets, Japan & ANZ transition in final phase
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Receives registration of Valganciclovir powder for oral solution in Germany
Leading USA based genetic testing brand officially enters the Indian market
Subscribe To Our Newsletter & Stay Updated
